Intralesional Avirulent Bacillus Calmette-Guérin Injection as a Promising Method for the Treatment of Tuberculosis Verrucosa Cutis

Cutaneous involvement is a relatively uncommon manifestation of tuberculosis (TB), particularly outside the endemic regions. Cutaneous TB manifests itself in various clinical forms, depending on the host's immune status and mode of transmission. Nonetheless, the same treatment regimen is recomm...

Full description

Saved in:
Bibliographic Details
Main Authors: Özgür Gündüz (Author), Gülşah Koçak (Author), Birgül Kaçmaz (Author), Tuba Devrim (Author), Hülya Şimşek (Author)
Format: Book
Published: Karger Publishers, 2022-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_17bac2a35c824308919b6edabeb6ce86
042 |a dc 
100 1 0 |a Özgür Gündüz  |e author 
700 1 0 |a Gülşah Koçak  |e author 
700 1 0 |a Birgül Kaçmaz  |e author 
700 1 0 |a Tuba Devrim  |e author 
700 1 0 |a Hülya Şimşek  |e author 
245 0 0 |a Intralesional Avirulent Bacillus Calmette-Guérin Injection as a Promising Method for the Treatment of Tuberculosis Verrucosa Cutis 
260 |b Karger Publishers,   |c 2022-03-01T00:00:00Z. 
500 |a 1662-6567 
500 |a 10.1159/000523797 
520 |a Cutaneous involvement is a relatively uncommon manifestation of tuberculosis (TB), particularly outside the endemic regions. Cutaneous TB manifests itself in various clinical forms, depending on the host's immune status and mode of transmission. Nonetheless, the same treatment regimen is recommended for every subtype. Tuberculosis verrucosa cutis (TBVC) is a specific subgroup in which the affected persons are usually healthy adults who are vaccinated or exposed to mycobacteria during their occupational activities. These patients have the ability to launch a strong cellular immune reaction against mycobacteria. In this article, we present an elderly patient with a 4-year history of TBVC who was treated with intralesional injection of avirulent Bacillus Calmette-Guérin (BCG) and report our clinical observation on the inflammatory and healing process of the patient's lesion following the intralesional BCG injection. 
546 |a EN 
690 |a tuberculosis verrucosa cutis 
690 |a bacillus calmette-guérin 
690 |a immunotherapy 
690 |a Dermatology 
690 |a RL1-803 
655 7 |a article  |2 local 
786 0 |n Case Reports in Dermatology, Vol 14, Iss 1, Pp 49-54 (2022) 
787 0 |n https://www.karger.com/Article/FullText/523797 
787 0 |n https://doaj.org/toc/1662-6567 
856 4 1 |u https://doaj.org/article/17bac2a35c824308919b6edabeb6ce86  |z Connect to this object online.